Patient 2: Cytometric data on diagnosis: the graphs show co-expression of CD13 (a) 
frequent chromosomal abnormality in childhood B cell precursor acute lymphoblastic leukemia (BCP-ALL) occurring in 20-25% of childhood ALL. 1, 2 The result of this translocation is the TEL-AML1 (ETV6-CBFA2) fusion gene detected only by FISH and/or by RT-PCR. The precise role of this event in leukemogenesis has not been completely elucidated thus far. According to Wiemels et al, 3 the TEL-AML1 gene fusion is shown to have originated in the prenatal period based on detecting TEL-AML1 fusion sequence in identical twins and in neonatal blood spot of children with ALL. 4 However, the latency between the birth and the onset of leukemia clearly demonstrates the need for important secondary and post-natal events in the promotion of ALL with TEL-AML1 fusion. Many secondary chromosomal changes
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Figure 1
FISH in patient 1 with LSI ES TEL/AML1 DNA probe (Vysis) shows double red/green (yellow) fusion TEL/AML1 signals (arrows) in metaphase cell (for identification of chromosomes includes black and white inset) as well as in interphase cells.
have since been described in association with TEL-AML1 fusion. Deletion of the other TEL allele is most frequently encountered. The duplication of the fusion gene is rare but has been recognized as the presence of additional der(21)t(12;21)(5,6) or ider(21)(q10)t(12;21) (p12;q22). 7 We present our observation of a duplication of the TEL/AML1 fusion gene at the time of diagnosis in childhood ALL as a further contribution to secondary changes in TEL/AML1-positive ALL patients. We would also point out that different pathways exist by which it may arise.
In our cohort of 67 childhood patients with BCP-ALL, 17 (25.3%) patients were TEL/AML1-positive. In 12 (70.7%) patients TEL/AML1 fusion signal arose from a single translocation, in three (17.6%) as the result of complex translocation and in two (11.7%) patients we found duplication of TEL/AML1 fusion signal in both metaphase and interphase cells. We present the last two cases in this report.
Case report 1: a 2.5-year-old girl was diagnosed as having ALL at the Department of Pediatrics, University Hospital, Olomouc. Some initial laboratory results are shown in Table 1 . The patient was enrolled on the standard risk ALL-BFM-95 protocol. At day 5 bone marrow showed a reduction of lymphoblasts to 3.2% and at day 33 to 0.8% when complete remission was achieved. The patient is now in first complete remission.
Cytogenetic analysis was performed on metaphase chromosomes from unstimulated bone marrow short-term culture, G-banded with conventional trypsin-Giemsa-Leishman technique. Cytogenetic analysis revealed two clones with the following karyotype: 46,XX in 13 (Figure 1 ). The final karyotypes according to conventional cytogenetics and FISH are shown in Table 1 . Case report 2: the second patient is a 3-year-old girl diagnosed at the Department of Pediatric Oncology, University Hospital, Brno. The laboratory data are shown in Table 1 . The patient was also enrolled on the standard risk ALL-BFM-95 protocol. At day 15 bone marrow aspirate proved a lymphoblast reduction to only 0.8% and at day 33 no blasts were present. Complete remission was achieved by day 33 according to the criteria of the ALL-BFM-95 protocol. She is still in first complete remission after 5 months of the above-mentioned treatment protocol.
A cytogenetic analysis, which was performed at the time of diagnosis from bone marrow cells, revealed two abnormal clones with karyotypes: 46,XX,del(6q) in five mitoses and 46,XX,del(6) (q23),add (20) Figure 2) . Evaluation of hybridization with LSI TEL/AML1 probe we showed in 15% of cells the presence of one fusion TEL/AML1 signal and in 57% of evaluated cells two fusion signals. The reciprocal AML1 signal was observed on 12p. Interphase FISH also revealed the presence of normal cells in 28%. We evaluated 300 bone marrow cells. The final karyotypes are described in Table 1 .
Detailed FISH analysis revealed in our two patients the presence of two fusion TEL/AML1 fusion signals which display two different pathways of the duplication of the TEL/AML1 fusion gene. The first case confirmed the presence of a trisomy of chromosome 21 and that both derivative chromosomes 21 carry the fusion gene TEL/AML1. The mechanism of origin of the trisomy of chromosome 21 perhaps corresponds to a mitotic nondisjunction with the preferential involvement of the derivative chromosome 21 bearing the TEL/AML1 fusion signal. According to our knowledge, this type of duplication of TEL/AML1 has been described in the literature only in relapsed patients. 5 The second of our observations of duplication of TEL/AML1 has not been described in the literature as yet. In this observation we found one fusion signal on chromosome 21 and a second fusion signal on the long arm of chromosome 20. The pathway of this aberration is quite different from the above-mentioned and is composed of two steps. The first step is the duplication of the TEL/AML1 fusion gene and the next one involves the translocation of the TEL/AML1 fusion Our observation confirms the existence of further secondary chromosomal change(s), eg the duplication of TEL/AML1 fusion gene at the time of diagnosis of ALL, which may also contribute to the process of leukemogenesis.
The cases presented here also prove that the FISH method, together with conventional cytogenetic techniques, are important to identify duplication and other crypric rearrangements involving TEL/AML1 genes.
